GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting 350 enrolled Genmab BioNTech SE · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.

Timeline

Start: 2019-09-17
Primary completion: 2025-12-30
Completion: 2027-01

Publications

Muik A, Adams 3rd HC, Gieseke F, Altintas I, Schoedel KB, Blum JM, Sanger B, Burm SM, Stanganello E, Verzijl D, Spires VM, Vascotto F, Toker A, Quinkhardt J, Fereshteh M, Diken M, Satijn DPE, Kreiter S, Ahmadi T, Breij ECW, Tureci O, Sasser K, Sahin U, Jure-Kunkel M. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022 Jun;10(6):e004322. doi: 10.1136/jitc-2021-004322.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GEN1042	Unknown	—	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous
Background	Cisplatin	Other / unclassified	—	Intravenous
Background	Gemcitabine	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous
Background	Pembrolizumab	Monoclonal antibody	—	Intravenous
Background	Pemetrexed	Small molecule	—	Intravenous
Background	fluorouracil	Small molecule	—	Intravenous

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Summary

Timeline

Publications

Drugs

Indications